DexCom, Inc. (NASDAQ:DXCM) Shares Acquired by National Pension Service

National Pension Service increased its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 2.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 874,115 shares of the medical device company’s stock after purchasing an additional 22,931 shares during the quarter. National Pension Service owned 0.23% of DexCom worth $108,469,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Sands Capital Management LLC boosted its holdings in shares of DexCom by 4.3% in the third quarter. Sands Capital Management LLC now owns 13,660,670 shares of the medical device company’s stock valued at $1,274,541,000 after acquiring an additional 557,543 shares in the last quarter. Blair William & Co. IL increased its position in DexCom by 1.7% during the 3rd quarter. Blair William & Co. IL now owns 4,507,153 shares of the medical device company’s stock worth $420,517,000 after purchasing an additional 73,654 shares during the period. Northern Trust Corp raised its stake in shares of DexCom by 2.4% during the 3rd quarter. Northern Trust Corp now owns 3,896,515 shares of the medical device company’s stock worth $363,545,000 after buying an additional 91,249 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of DexCom by 3.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,241,701 shares of the medical device company’s stock valued at $278,173,000 after buying an additional 80,740 shares during the period. Finally, Winslow Capital Management LLC purchased a new stake in shares of DexCom in the third quarter valued at approximately $173,120,000. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. Royal Bank of Canada started coverage on DexCom in a report on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 target price for the company. Citigroup boosted their price objective on shares of DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a report on Wednesday, April 3rd. Canaccord Genuity Group increased their target price on shares of DexCom from $144.00 to $145.00 and gave the company a “buy” rating in a report on Friday, April 26th. UBS Group lifted their price target on shares of DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a research report on Wednesday, April 10th. Finally, Raymond James upped their price target on DexCom from $151.00 to $160.00 and gave the stock a “strong-buy” rating in a report on Friday, April 26th. Two analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $141.67.

DexCom Trading Down 2.1 %

Shares of NASDAQ:DXCM traded down $2.68 during trading on Wednesday, reaching $127.42. The stock had a trading volume of 1,336,567 shares, compared to its average volume of 2,981,269. The company has a quick ratio of 2.53, a current ratio of 2.90 and a debt-to-equity ratio of 1.08. The stock has a market cap of $50.67 billion, a P/E ratio of 82.21, a PEG ratio of 2.19 and a beta of 1.23. The business has a fifty day moving average price of $132.94 and a 200-day moving average price of $121.16. DexCom, Inc. has a fifty-two week low of $74.75 and a fifty-two week high of $142.00.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, April 25th. The medical device company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.05. DexCom had a return on equity of 31.01% and a net margin of 16.82%. The company had revenue of $921.00 million for the quarter, compared to analyst estimates of $911.20 million. As a group, analysts anticipate that DexCom, Inc. will post 1.78 earnings per share for the current fiscal year.

Insider Buying and Selling at DexCom

In related news, EVP Sadie Stern sold 20,321 shares of the business’s stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $133.61, for a total value of $2,715,088.81. Following the completion of the sale, the executive vice president now directly owns 80,441 shares in the company, valued at $10,747,722.01. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, EVP Sadie Stern sold 20,321 shares of DexCom stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $133.61, for a total value of $2,715,088.81. Following the transaction, the executive vice president now owns 80,441 shares in the company, valued at $10,747,722.01. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Jereme M. Sylvain sold 3,363 shares of the business’s stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $116.73, for a total value of $392,562.99. Following the sale, the chief financial officer now directly owns 71,142 shares of the company’s stock, valued at approximately $8,304,405.66. The disclosure for this sale can be found here. Insiders sold 190,004 shares of company stock worth $25,610,270 in the last 90 days. 0.41% of the stock is owned by company insiders.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.